Brief: Macrogenics And Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement
04/05/2026 12:35
May 4 (Reuters) - MacroGenics Inc MGNX.O: MACROGENICS AND SAGARD HEALTHCARE PARTNERS ENTER INTO EXPANDED ZYNYZ® ROYALTY PURCHASE AGREEMENT MACROGENICS INC - RECEIVES $60 MILLION UPFRONT, ELIGIBLE FOR UP TO $20 MILLION 2026 MILESTONE MACROGENICS INC - ALL ROYALTY RIGHTS REVERT TO MACROGENICS AFTER SAGARD RECEIVES 1.7X OR 2.0X INVESTMENT BY SEPTEMBER 30, 2032 Source text: ID:nGNX1mtmZY Further company coverage: MGNX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MacroGenics
See all newsMacroGenics Q1 revenue rises, beats estimates on client production and cancer drug royalties
Brief: MacroGenics Q1 Net Income USD -36.8 Million
NASDAQ RESUMED AT 05:45 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:25 PM
Brief: Macrogenics And Sagard Healthcare Partners Enter Into Expanded Zynyz® Royalty Purchase Agreement